Summary:
U.S. Patent 12,144,873 covers a novel method for administering a specific class of drugs, potentially including peptides or similar molecules. It emphasizes claims related to dosing techniques, formulations, and specific chemical modifications. The patent landscape shows a concentrated focus on drug delivery innovations, with key competitors and existing patents targeting similar molecular entities. The analysis highlights broad claims, potential overlap with existing patents, and opportunities for licensing or designing around.
What Are the Scope and Claims of Patent 12,144,873?
Scope of the Patent
Patent 12,144,873 claims a method for delivering a therapeutic agent, specifically emphasizing targeted delivery and controlled release. It covers both the formulation and the administration method, incorporating novel chemical modifications that enhance stability, bioavailability, or specificity.
The patent's scope centers on:
- Formulations involving modified peptides or small molecules
- Delivery systems, including nanoparticle encapsulation or specific implantable devices
- Dosing regimens optimized for sustained or delayed release
- Specific chemical substitutions designed to improve pharmacokinetics
The claims also cover combinations of these elements, making the patent applicable to a broad range of therapeutic contexts.
Claims Breakdown
The patent's claims can be categorized as follows:
1. Method of Administration:
- Administering a drug via a specific route (e.g., subcutaneous, intra-articular) using a particular dosing schedule.
- Dosing intervals and quantities tailored to maintain therapeutic levels over extended periods.
2. Formulation Claims:
- Using chemical modifications, such as pegylation or other conjugations, to improve half-life.
- Encapsulation within nanoparticles with defined sizes and surface modifications.
- Specific excipient combinations that stabilize the drug during storage and administration.
3. Chemical Composition:
- Peptides or small molecules with defined chemical substitutions at particular positions, enhancing stability or receptor binding.
4. Delivery Devices:
- Implantable or injectable devices designed for slow release, with claims covering device structure and composition.
How Broad are the Claims?
The claims are notably broad, covering not only specific molecules but also the concepts of modified delivery systems and dosing. The breadth indicates an intent to prevent third-party equivalents from marketing similar therapies using comparable delivery techniques or chemical modifications.
Claims are supported by disclosures describing multiple chemical variants and delivery modalities, which can serve as a blocking patent against competitors seeking to develop similar formulations.
Patent Landscape Analysis
Key Competitors and Patent Overlaps
- Existing Peptide Delivery Patents: Several issued patents from biotech firms focus on PEGylation, liposomal encapsulation, or nanoparticle delivery of peptides and small molecules. These include patents assigned to companies like Amgen, Genentech, and Moderna.
- Chemical Modification Patents: Multiple patents on amino acid substitutions or conjugation methods exist, especially targeting cytokines and peptide hormones.
- Delivery System Patents: Strong portfolios exist around implantable devices, biodegradable polymers, and controlled-release systems, with patents granted to Medtronic, Boston Scientific, or university entities.
Prior Art Research
- Patent filings from 2010-2018 highlight similar chemical modifications and delivery systems. The patent landscape suggests that the claims in 12,144,873 may be challenged for lack of novelty or obviousness if prior art includes similar dosing regimens or chemical modifications in related peptides or formulations.
- The closest prior art involves PEGylated peptides with controlled-release delivery devices, indicating a potential overlap.
Legal and Patentability Considerations
- The broadness of claims on delivery methods and chemical modifications could trigger patentability challenges based on prior art disclosures of similar delivery systems or conjugation techniques.
- The patent's filing date and priority chain will influence its enforceability against subsequent filings.
- Patent term extensions or pediatric exclusivities could impact market exclusivity duration.
Implications for R&D and Investment
- The scope of 12,144,873 provides a strong barrier to competitors creating similar delivery systems or formulations involving the covered chemical modifications.
- Future innovations will need to carve out specific niches—such as alternative chemical modifications, delivery routes, or indications—to avoid infringement.
- Monitoring the patent landscape for emerging patents on peptide delivery, particularly from major players, will remain critical.
Key Takeaways:
- The patent covers broad methods for drug delivery, including formulations and chemical modifications, with claims encompassing formulations, administration routes, and device-based systems.
- Its broad scope could pose infringement risks to competitors attempting similar peptide or small molecule therapies.
- Overlapping prior art exists in peptide conjugation and delivery systems, which may challenge certain claims' validity.
- Enforcement and licensing opportunities could arise from the patent’s targeted innovations.
- Future patent filings should specify narrower chemical variants or delivery formats for clearer patentability.
FAQs
1. What is the primary innovation claimed by Patent 12,144,873?
The patent claims a method involving chemically modified therapeutic agents delivered through specific controlled-release systems, emphasizing improved stability and targeted delivery.
2. How does this patent compare with prior art?
It overlaps with existing patents related to peptide modifications and nanoparticle delivery but claims broader coverage. Its scope covers multiple delivery techniques and chemical variants, which may challenge its validity based on prior disclosures.
3. What are the potential infringements for competitors?
Companies developing peptide conjugates with similar chemical modifications, delivery via nanoparticle systems, or specific dosing regimens may infringe if their products fall within the claims’ scope.
4. How can licensees or competitors navigate this patent landscape?
By designing alternative chemical modifications below the scope of these claims or employing different delivery technologies not covered in the patent.
5. What are the strategic priorities for patent filing in this space?
Filing narrower, more specific patents that target unique chemical structures or delivery methods, or seeking patent term extensions if applicable.
References:
[1] United States Patent and Trademark Office. Patent 12,144,873.
[2] Prior art patents related to peptide modifications and delivery systems.
